BAC
Bank of America Corporation
BAC has the edge over NRDS overall, supported by stronger modeled upside and lower modeled downside.
NRDS
NerdWallet, Inc.
NRDS offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
NRDS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| N/A | |
| N/A |
NRDS's revenue and profitability are currently stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like NRDS.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC's PE is in its fair range at 12x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
NRDS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 9.4x | $7.31 | — |
| Cheap | 11x | $8.58 | +17% |
| Forward | 11x | $7.31 | — |
| Fair | 19x | $14.91 | +104% |
| Expensive | 246x | $192 | +2522% |
Historical ranges are pointers, not guarantees.
NRDS has the edge over BAC in the historical PE scenario, which offers more potential upside but is not a forecast.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
BAC has the edge over NRDS on the outlook, with more favorable valuation and earnings expectations.
NRDS Forward outlook
| Metric | Outlook |
|---|---|
| Deteriorating | |
| Strong decline | |
| Stable | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect NRDS's earnings and profitability to decline, with its revenue holding steady. However, they disagree widely on these estimates.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC has the edge over NRDS on earnings, with more consistent year-over-year improvement.
NRDS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.67 | -15% |
| Q3 2026 | $0.78 | -17% |
| Q2 2026 | $0.89 | +48% |
| Q1 2026 | $0.93 | +151% |
| Q4 2025 | $0.64 | +68% |
| Q3 2025 | $0.94 | +$1.07 |
| Q2 2025 | $0.60 | +$0.74 |
| Q1 2025 | $0.37 | +$0.53 |
| Q4 2024 | $0.38 | +$0.53 |
NRDS earned $0.78 per share over the past year, down 17% from the year before.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC's revenue has grown year over year for 10 quarters in a row: $30B last quarter, up 6.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC has the edge over NRDS on profitability, with a higher operating margin.
NRDS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $239.6M | +11% |
| Q2 2026 | $197.3M | +5.6% |
| Q1 2026 | $222.2M | +6.2% |
| Q4 2025 | $225.4M | +23% |
| Q3 2025 | $215.1M | +12% |
| Q2 2025 | $186.9M | +24% |
| Q1 2025 | $209.2M | +29% |
| Q4 2024 | $183.8M | +37% |
NRDS has the edge over BAC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 8.1% | -7.9 points |
| Q2 2026 | 3.5% | -2.2 points |
| Q1 2026 | 12% | +12 points |
| Q4 2025 | 8.6% | +3.9 points |
| Q3 2025 | 16% | +13 points |
| Q2 2025 | 5.7% | +12 points |
| Q1 2025 | 0.3% | -2 points |
| Q4 2024 | 4.7% | +1.3 points |
NRDS's operating margin was 8.1% last quarter, down 7.9 points from the same quarter a year ago.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
NRDS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $31M | -36% |
| Q2 2026 | $41.1M | +145% |
| Q1 2026 | $35.3M | +33% |
| Q4 2025 | $38.6M | +298% |
| Q3 2025 | $48.4M | +67% |
| Q2 2025 | $16.8M | +70% |
| Q1 2025 | $26.5M | +17% |
| Q4 2024 | $9.7M | -67% |
NRDS has the edge over BAC on cash flow, with more consistent year-over-year improvement.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has 7.2B diluted shares, down 5.3% from a year ago, with $25.6B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
NRDS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.7% | -1.1M shares |
| 1 year | -16% | -12.2M shares |
| 3 years | -17% | -12.8M shares |
| 5 years | -0.1% | -47.3K shares |
| Available history | +17% | +9.6M shares |
NRDS has the edge over BAC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $10.5M |
| Q2 2026 | $22.8M |
| Q1 2026 | $66M |
| Q4 2025 | $50.7M |
| Q3 2025 | $19.2M |
| Q3 2024 | $68.7M |
| Q3 2023 | $10.8M |
| Q4 2021 | — |
NRDS spent $150M buying back its own shares over the past year.
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
NRDS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.7x | Net Cash |
| Q2 2026 | -0.5x | Net Cash |
| Q1 2026 | -0.4x | Net Cash |
| Q4 2025 | -0.8x | Net Cash |
| Q3 2025 | -1.2x | Net Cash |
| Q2 2025 | -1.4x | Net Cash |
| Q1 2025 | -1.7x | Net Cash |
| Q4 2024 | -1.1x | Net Cash |
NRDS has the edge over BAC on leverage, with a lower net debt burden relative to earnings.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
NRDS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.8 | Neutral |
| Stochastic | 31.1 | Neutral |
NRDS's weekly RSI is 37 (neutral) and its Stochastic is 31 (neutral).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC is trading at 12x earnings, in line with the Financial Services sector's median of 13x.
NRDS PE vs Financial Services Sector
| Metric | NRDS | Sector median | Relative |
|---|---|---|---|
| PE | 9.4x | 13x | 28% below |
| PE % | 5 | 64 | 59 pts below |
NRDS has the edge over BAC on valuation relative to its sector.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has the edge over NRDS on trend strength, trading above more of its moving averages.
NRDS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.28 | 21% below |
| 20 week MA | $9.41 | 22% below |
| 50 week MA | $10.3 | 29% below |
| 100 week MA | $10.8 | 32% below |
| 200 week MA | $11.8 | 38% below |
NRDS is in a downtrend: it's below all five of its weekly moving averages, and 38% below its 200-week average.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has the edge over NRDS on returns for 2026, with the stronger performance.
NRDS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $25.9 | $15.1 | -42% |
| 2022 | $15.1 | $8.99 | -41% |
| 2023 | $8.99 | $14.7 | +64% |
| 2024 | $14.7 | $13.2 | -11% |
| 2025 | $13.2 | $13.9 | +5.8% |
| 2026 YTD | $13.9 | $7.31 | -48% |
NRDS has finished lower in three of the last five years. It's down 48% so far in 2026.